IBCSG 35-07 (SOLE)

  • A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node-positive early stage breast cancer.

    Study Of Letrozole Extension (SOLE)

  • Study Chairs
    Dr. Marco Colleoni - Milano, Italy

    Statisticians
    Dr. Meredith Regan

    Trial Coordinator
    Meredith Kissel

    Data Managers
    Monica Greco, Adriana Karausch

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    November 8, 2007

    Final Accrual
    4884 patients

    Targeted Accrual
    4800 patients

    Date of closure
    October 8, 2012

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login